The company
SOPHiA GENETICS SA -
SOPH · Nasdaq
SOPH stood above a rising 150-day average in 49 of the last 52 weekly readings, including each of the last 20 weeks. It is 18.7% above that average now. Payments & Processors: 40% of its 67 stocks in an uptrend (−3 points in four weeks); Financials: 49% (−4 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 20 in a row
- Industry in uptrend
- 40% -3 in 4 wk
- Insider buys, 12 months
- $198K
- Insider sales, 12 months
- $9.6M
- Officials’ trades on record
- 0
- Institutions holding
- 70 (+22)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 49 of 52 weeks.
Payments & Processors: About half its stocks are in an uptrend and the share has held steady. Financials: About half its stocks are in an uptrend and the share has been slipping.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Zhenyu XuChief Scientific Officer | sold | 4,000at $7.18 | 13 Oct 2026filed 14 Oct 2026 |
| Jurgi CamblongExecutive Chairman | sold | 8,500at $7.26 | 12 Oct 2026filed 14 Oct 2026 |
| Philippe MenuChief Medical Officer | sold | 5,000at $7.26 | 12 Oct 2026filed 14 Oct 2026 |
| Ross MukenChief Executive Officer | sold | 9,838at $8.13 | 5 Oct 2026filed 7 Oct 2026 |
| Zhenyu XuChief Scientific Officer | sold | 7,394at $8.12 | 5 Oct 2026filed 7 Oct 2026 |
| Jurgi CamblongExecutive Chairman | sold | 40,172at $8.13 | 5 Oct 2026filed 7 Oct 2026 |
| Philippe MenuChief Medical Officer | sold | 7,394at $8.13 | 5 Oct 2026filed 7 Oct 2026 |
| George CardozaChief Financial Officer | sold | 1,592at $8.10 | 5 Oct 2026filed 7 Oct 2026 |
| Kevin PuylaertChief Sales Officer | sold | 185at $8.06 | 5 Oct 2026filed 7 Oct 2026 |
| Kevin PuylaertChief Sales Officer | sold | 31at $7.92 | 5 Oct 2026filed 7 Oct 2026 |
| Abhimanyu VermaChief Technology Officer | sold | 5,284at $8.12 | 5 Oct 2026filed 7 Oct 2026 |
| Manuela ValenteChief People Officer | sold | 4,240at $8.13 | 5 Oct 2026filed 7 Oct 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| GENERATION INVESTMENT MANAGEMENT LLPunchanged · filed 10 Aug 2026 | 6,789,560$39.2M | 00.0% |
| AIGH Capital Management LLCnew · filed 7 Aug 2026 | 3,954,194$22.8M | +3,954,194 |
| AKRE CAPITAL MANAGEMENT LLCunchanged · filed 14 Aug 2026 | 3,719,140$21.5M | 00.0% |
| ROYCE & ASSOCIATES LPadded · filed 14 Aug 2026 | 3,381,736$19.5M | +1,565,424+86.2% |
| PRINCIPAL FINANCIAL GROUP INCadded · filed 4 Aug 2026 | 2,364,256$13.6M | +955,014+67.8% |
| AMERIPRISE FINANCIAL INCnew · filed 14 Aug 2026 | 2,216,752$12.8M | +2,216,752 |
| BANQUE PICTET & CIE SAunchanged · filed 24 Jul 2026 | 2,208,280$12.7M | 00.0% |
| AWM Investment Company, Inc.new · filed 14 Aug 2026 | 1,700,000$9.8M | +1,700,000 |
| Soleus Capital Management, L.P.reduced · filed 11 Aug 2026 | 1,565,000$9.0M | -285,000−15.4% |
| SILVERCREST ASSET MANAGEMENT GROUP LLCnew · filed 14 Aug 2026 | 1,428,470$8.2M | +1,428,470 |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.